SCHEMBL4122382

SCHEMBL4122382

CS(=O)(=O)c1ccc(-c2ccccc2)c(C(=O)O)c1F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACLY P53396 3/20 0.44
PTGS2 P35354 7/20 0.41
FABP4 P15090 1/20 0.40
FABP5 Q01469 1/20 0.40
AGTR1 P30556 1/20 0.38
FOLH1 Q04609 1/20 0.38
PTGS1 P23219 3/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
FABP2 P12104 1/20 0.37
TSHR P16473 1/20 0.37
AKR1C4 P17516 1/20 0.37
ADRA2B P18089 1/20 0.37
CHRM3 P20309 1/20 0.37
HTR2C P28335 1/20 0.37
DRD3 P35462 1/20 0.37
AKR1C3 P42330 1/20 0.37
AKR1C2 P52895 1/20 0.37
AKR1C1 Q04828 1/20 0.37
SLC22A6 Q4U2R8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4116177 0.86 ACLY (0.37) ACLYFABP4FABP5MEN1KMT2A
SCHEMBL4422508 0.78 FABP4 (0.44) ACLYFABP4MEN1KMT2A
SCHEMBL9954274 0.77 MEN1 (0.43) PTGS2FOLH1PTGS1MEN1KMT2A
SCHEMBL8915221 0.76 FOLH1 (0.44) ACLYPTGS2FABP4FABP5FOLH1
SCHEMBL4116181 0.76 ACLY (0.39) ACLYPTGS2AGTR1PTGS1MEN1
SCHEMBL28022697 0.75 PTGS2 (0.52) ACLYPTGS2PTGS1KMT2ACYP1A2
SCHEMBL751337 0.73 FOLH1 (0.41) PTGS2FABP4FABP5AGTR1FOLH1
SCHEMBL14322385 0.73 CA12 (0.49) ACLYFABP4FABP5MEN1KMT2A
SCHEMBL23521242 0.73 FOLH1 (0.53) FABP4FABP5FOLH1MEN1KMT2A
SCHEMBL3431160 0.72 FOLH1 (0.47) PTGS2FOLH1PTGS1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188139-B2 Heterocyclic-substituted phenyl methanones HOFFMAN-LA ROCHE INC. (US) 2012-05-29 US disclosed
CN-101119968-B Heterocyclically substituted phenyl methanone derivatives as glycine transporter 1 inhibitors HOFFMANN LA ROCHE 2011-08-31 CN disclosed
US-20090203665-A1 HETEROCYCLIC-SUBSTITUTED PHENYL METHANONES JOLIDON SYNESE 2009-08-13 US disclosed
US-7557114-B2 Heterocyclic-substituted phenyl methanones HOFFMAN-LA ROCHE INC. (US) 2009-07-07 US disclosed
CN-101119968-A Heterocyclically substituted phenyl methanone derivatives as glycine transporter 1 inhibitors HOFFMANN LA ROCHE (CH) 2008-02-06 CN disclosed
US-20060178381-A1 Heterocyclic-substituted phenyl methanones HOFFMANN-LA ROCHE INC. 2006-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203665-A1 HETEROCYCLIC-SUBSTITUTED PHENYL METHANONES CYP2B6, CYP2D6, CYP1A2 ACLY 1213/4885PTGS2 1021/4885FABP4 3916/4885
US-20060178381-A1 Heterocyclic-substituted phenyl methanones CYP2B6, CYP2D6, CYP1A2 ACLY 1213/4885PTGS2 1021/4885FABP4 3916/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.